Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 6 of 114

  1. 6% hydroxyethyl starch 130/0.4

    Fresenius Kabi Australia Pty Limited

    Hypovolemia

    phase 3 small molecule completed

    1 trial

  2. 6-Thio-2'-Deoxyguanosine

    MAIA Biotechnology

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule active

    2 trials

  3. 6-month course of antiandrogen drugs

    The First People's Hospital of Lianyungang

    Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

    phase 3 small molecule active

    1 trial

  4. 60 mg ulixacaltamide

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 3 small molecule active

    1 trial

  5. 600 mg Ibuprofen

    United Therapeutics Europe Ltd

    Tibial Fractures

    phase 3 small molecule active

    1 trial

  6. 601 1.25mg

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Branch Retinal Vein Occlusion

    phase 3 small molecule completed

    2 trials

  7. 608

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Axial Spondyloarthritis, Non-Radiographic

    phase 3 small molecule active

    1 trial

  8. 608 Q2W

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Plaque Psoriasis Patients

    phase 3 small molecule active

    1 trial

  9. 608 Q2W

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Psoriasis

    phase 3 small molecule completed

    1 trial

  10. 608 dose

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Ankylosing Spondylitis

    phase 3 small molecule active

    1 trial

  11. 610

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Asthma

    phase 3 small molecule active

    2 trials

  12. 611

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Pulmonary Disease, Chronic Obstructive (COPD)

    phase 3 small molecule active

    1 trial

  13. 611

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Sinusitis

    phase 3 small molecule active

    2 trials

  14. 611

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Dermatitis, Atopic

    phase 3 small molecule active

    3 trials

  15. 61186372COR3001

    Janssen-Cilag International N.V.

    KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    phase 3 small molecule active

    1 trial

  16. 61186372COR3002

    Janssen-Cilag International N.V.

    KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  17. 61186372HNC3001

    Janssen-Cilag International N.V.

    Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  18. 61186372NSC3001

    Janssen-Cilag International N.V.

    EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  19. 61186372NSC3002

    Janssen-Cilag International N.V.

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  20. 61186372NSC3004

    Janssen-Cilag International N.V.

    EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  21. 63935937MDS3001

    Geron Netherlands B.V.

    Myelodysplastic syndromes (MDS)

    phase 3 small molecule active

    1 trial

  22. 64007957MMY3005

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  23. 64007957MMY3006

    Janssen-Cilag International N.V.

    Relapsed/refractory multiple myeloma

    phase 3 small molecule active

    1 trial

  24. 64091742PCR3001

    Janssen-Cilag International N.V.

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  25. 64407564MMY3002

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  26. 64407564MMY3009

    Janssen-Cilag International N.V.

    Relapsed or Refractory Myeloma

    phase 3 small molecule active

    1 trial

  27. 64Cu(II)Cl2 solution for injection

    A.C.O.M. - Advanced Center Oncology

    Cancer on the prostatic bed

    phase 3 small molecule active

    1 trial

  28. 64Cu-PSMA I&T

    Curium Romania S.R.L.

    Prostate cancer

    phase 3 small molecule active

    1 trial

  29. 64Cu-PSMA I&T

    Curium Romania S.R.L.

    Prostate cancer

    phase 3 small molecule active

    1 trial

  30. 6520-9970-08

    Medice Arzneimittel Pütter GmbH & Co. KG

    Patients with ADHD (according to ICD-10 / DSM-5)

    phase 3 small molecule active

    1 trial

  31. 6630-9450-01

    Medice Arzneimittel Pütter GmbH & Co. KG

    acute pharyngitis

    phase 3 small molecule active

    1 trial

  32. 6630-9450-01

    Medice Arzneimittel Pütter GmbH & Co. KG

    acute pharyngitis

    phase 3 small molecule active

    1 trial

  33. 67652000PCR3002

    Janssen-Cilag International N.V.

    Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    phase 3 small molecule active

    1 trial

  34. 68284528MMY3002

    Janssen-Cilag International N.V.

    Relapsed and Lenalidomide-Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  35. 68284528MMY3004

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  36. 68Ga-PSMA-11

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biochemical Recurrence of Malignant Neoplasm of Prostate

    phase 3 small molecule active

    1 trial

  37. 68Ga-PSMA-11

    Telix Innovations

    PCA

    phase 3 small molecule active

    1 trial

  38. 700 µg Dexamethasone

    Allergan Pharmaceuticals International Limited

    Macular Edema

    phase 3 small molecule completed

    1 trial

  39. 72189812

    Lacuna Pharma Pty Ltd

    Bipolar I Disorder

    phase 3 small molecule active

    1 trial

  40. 73841937NSC3003

    Janssen-Cilag International N.V.

    EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  41. 7465-CL-0301

    Astellas Pharma GmbH

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  42. 747-308

    Lacuna Pharma Pty Ltd

    Biliary Atresia, Post-hepatoportoenterostomy

    phase 3 small molecule active

    1 trial

  43. 750 mg Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Generalized Pustular Psoriasis

    phase 3 small molecule completed

    1 trial

  44. 75276617AML3001

    Janssen-Cilag International N.V.

    Acute Myeloid Luekemia

    phase 3 small molecule active

    1 trial

  45. 77242113CRD3001

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  46. 77242113PSA3001

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  47. 77242113PSO3001

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  48. 77242113PSO3002

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.